|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits with other banks | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Fed funds sold | ||||||||||||||||||||
| Investment securities — available-for-sale, net of allowance for credit losses of $0 at both June 30, 2026 and December 31, 2025 (amortized cost of $2,997,415 and $3,088,820 at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Investment securities — held-to-maturity, net of allowance for credit losses of $2,005 at both June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Total investment securities | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Loans receivable, net | ||||||||||||||||||||
| Bank premises and equipment, net | ||||||||||||||||||||
| Foreclosed assets held for sale | ||||||||||||||||||||
| Cash value of life insurance | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Deferred tax asset, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Core deposit intangibles | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Demand and non-interest-bearing | ||||||||||||||||||||
| Savings and interest-bearing transaction accounts | ||||||||||||||||||||
| Time deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Securities sold under agreements to repurchase | ||||||||||||||||||||
| FHLB and other borrowed funds | ||||||||||||||||||||
| Accrued interest payable and other liabilities | ||||||||||||||||||||
| Subordinated debentures | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Common stock, par value $0.01; shares authorized 400,000,000 in 2026 and 2025; shares issued and outstanding 200,460,097 in 2026 and 196,357,167 in 2025 | ||||||||||||||||||||
| Capital surplus | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
